Jonathan Baume

From Wikipedia, the free encyclopedia

Jonathan Edward Baume (born 13 July 1953 in Wakefield) was General Secretary of the FDA from 1997 until 2012 and a member of the General Council of the Trades Union Congress (TUC) from 2001 to 2012.

He was appointed as a Civil Service Commissioner in April 2012 [1] and is a Council member of the Advisory, Conciliation and Arbitration Service (Acas).

Education[edit]

He was educated at Queen Elizabeth Grammar School, Wakefield, and Keble College, Oxford (BA Hons 1974; MA). While at university, he was active in student politics as a member of the International Socialists and then the Trotskyist International Marxist Group, the British section of the Fourth International.[2]

Career[edit]

Following the announcement of Elizabeth Symons' resignation as General Secretary, the FDA National Executive interviewed several candidates to replace her and agreed to nominate Baume as her successor. However, former FDA member Tony Engel (who had not been interviewed) was also nominated as a candidate. In the subsequent ballot of the whole FDA membership, Baume was elected with 68% of the votes cast.

Jonathan Baume retired as FDA General Secretary in late 2012, and was succeeded by the then Deputy General Secretary, Dave Penman.

Government advisor[edit]

He has served on three Government advisory groups:

Outside interests[edit]

He is a member of the Campaign for the Protection of Rural England and the National Trust, and a Fellow of the Royal Society of Arts. After suffering from back problems, he took up yoga. His other hobbies are jazz, world music and rambling. He is a member of the Athenaeum Club.

References[edit]

  1. ^ "Archived copy" (PDF). Archived from the original (PDF) on 30 October 2012. Retrieved 10 February 2013.{{cite web}}: CS1 maint: archived copy as title (link)
  2. ^ "Archived copy". Archived from the original on 21 April 2008. Retrieved 4 April 2009.{{cite web}}: CS1 maint: archived copy as title (link)
Trade union offices
Preceded by General Secretary of the FDA
1997–2012
Succeeded by